Detalhe da pesquisa
1.
The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy.
Cancer Immunol Immunother
; 67(3): 381-392, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29124315
2.
Alveolar Differentiation Drives Resistance to KRAS Inhibition in Lung Adenocarcinoma.
Cancer Discov
; 14(2): 308-325, 2024 Feb 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37931288
3.
The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading.
Mol Cancer Ther
; : OF1-OF13, 2024 Jun 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38904222
4.
Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers.
Science
; 384(6700): eadk0775, 2024 Jun 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38843331
5.
The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading.
Mol Cancer Ther
; 2024 Apr 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38641404
6.
TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors.
Cancer Res
; 83(24): 4112-4129, 2023 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37934103
7.
Alveolar differentiation drives resistance to KRAS inhibition in lung adenocarcinoma.
bioRxiv
; 2023 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37808711
8.
Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer.
Cancer Discov
; 13(2): 298-311, 2023 02 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36472553
9.
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer.
Cancer Discov
; 13(11): 2412-2431, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37552839
10.
Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer.
Clin Cancer Res
; 28(15): 3318-3328, 2022 08 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35404402
11.
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor.
Nat Med
; 28(10): 2171-2182, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36216931
12.
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor.
J Med Chem
; 65(4): 3123-3133, 2022 02 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34889605
13.
The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy.
Mol Cancer Ther
; 20(6): 975-985, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33722854
14.
Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer.
J Med Chem
; 63(13): 6679-6693, 2020 07 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32250617
15.
The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.
Cancer Discov
; 10(1): 54-71, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31658955
16.
Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1.
Mol Cancer Ther
; 7(8): 2394-404, 2008 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-18723486
17.
Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity.
ACS Med Chem Lett
; 9(12): 1230-1234, 2018 Dec 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-30613331
18.
Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.
Clin Cancer Res
; 23(21): 6661-6672, 2017 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28765324
19.
Mitotic Checkpoint Kinase Mps1 Has a Role in Normal Physiology which Impacts Clinical Utility.
PLoS One
; 10(9): e0138616, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26398286
20.
Chemogenetic evaluation of the mitotic kinesin CENP-E reveals a critical role in triple-negative breast cancer.
Mol Cancer Ther
; 13(8): 2104-15, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24928852